Alpha Tau: Robust Safety and Efficacy Data from Multiple Clinical Trials

Alpha Tau Medical (Nasdaq: DRTS) has released initial long-term safety and tumor control outcomes for patients with unresectable, recurrent, or locally advanced head and neck or skin tumors treated with the company’s alpha-radiation cancer therapy Alpha DaRT™ across four prospective trials conducted at several international institutions.

A complete response (CR) was observed in 89% of treated lesions and 10% demonstrated a partial response.

Dr. Robert Den, Alpha Tau’s CMO, said, “These data answer an important question for Alpha Tau, namely, whether the strong short-term local responses we’ve seen will lead to long-term tumor control. The answer is a resounding yes, with a 77% durable tumor control rate at 2 years.”


Between February 2017 and December 2022, 81 lesions in 71 patients were treated with Alpha DaRT in four prospective feasibility trials whose objective was to assess early toxicity and tumor response outcomes

Twenty percent of patients developed treatment-related acute grade 2 toxicity (such as dermatitis radiation, local pain at the treatment site or pruritus), which subsequently resolved with conservative treatment.

Alpha Tau will continue to generate data from its U.S. pivotal multicenter ReSTART trial, its pancreatic cancer trial being conducted in Montreal, Canada, and other trials underway or scheduled to launch soon.

About Alpha Tau

Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

Share This Article


About the Author

Alpha Tau: Robust Safety and Efficacy Data from Multiple Clinical Trials

Editor Prism MarketView